Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab.

Saved in:
Bibliographic Details
Title: Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab.
Authors: Magnus CL; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Hiergeist A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Schuster P; Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany., Rohrhofer A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Medenbach J; Biochemistry I, Faculty of Biology and Pre-Clinical Medicine, University of Regensburg, Regensburg, Germany., Gessner A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.; Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany., Peterhoff D; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.; Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany., Schmidt B; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.; Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Source: Frontiers in immunology [Front Immunol] 2022 Aug 24; Vol. 13, pp. 966236. Date of Electronic Publication: 2022 Aug 24 (Print Publication: 2022).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2022.966236